^
Association details:
| Biomarker: | EGFR G719S |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | gefitinib (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Excerpt:
First-line gefitinib for patients with advanced non–small-cell lung cancer who were selected on the basis of EGFR mutations improved progression-free survival, with acceptable toxicity, as compared with standard chemotherapy.
DOI:
10.1056/NEJMoa0909530
Source:
Title:
Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients
Excerpt:
...- Activating EGFR mutations (G719A/C/S; Exon 19 insertion/deletion; L858R; L861Q)...
Trial ID:
Source:
Title:
Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non–Small Cell Lung Cancer
Excerpt:
Of the 33 patients with tumors positive for mutant EGFR, 4 patients had disease progression within 2 months of gefitinib treatment. All these tumors were squamous cell carcinoma and the patterns of mutation were delA767_V769 (exon 20), A763V mutation (exon 20), L858R mutation (exon 21), and a double substitution mutation, G719S and L861Q, in exons 18 and 21.
DOI:
10.1158/1078-0432.CCR-04-1981
Source:
Title:
Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants
Excerpt:
In different EGFR variant-expressing 32D cells, only cells harboring L858R, E746-A750 deletion, and G719S mutants were clearly more sensitive to gefitinib than wild-type EGFR-expressing cells.
DOI:
10.1038/sj.onc.1209159
